{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:23:47Z","timestamp":1787228627136,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tranon.2026.102921","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:30:04Z","timestamp":1784295004000},"page":"102921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Single-cell sequencing reveals an immunotherapy-relevant IFITM1-marked epithelial interferon state in nasopharyngeal carcinoma"],"prefix":"10.1016","volume":"71","author":[{"given":"Lun","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tranon.2026.102921_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.tranon.2026.102921_bib0002","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41588-019-0436-5","article-title":"Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma","volume":"51","author":"Xu","year":"2019","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.tranon.2026.102921_bib0003","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00405-017-4827-x","article-title":"Overexpression of osteopontin promotes cell proliferation and migration in human nasopharyngeal carcinoma and is associated with poor prognosis","volume":"275","author":"Qin","year":"2018","journal-title":"Eur. Arch. Otorhinolaryngol."},{"issue":"12","key":"10.1016\/j.tranon.2026.102921_bib0004","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.tranon.2026.102921_bib0005","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.tranon.2026.102921_bib0006","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102921_bib0007","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","article-title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial","volume":"34","author":"Chan","year":"2023","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2026.102921_bib0008","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/1541-7786.MCR-17-0134","article-title":"Genomic analysis of nasopharyngeal carcinoma reveals TME-based subtypes","volume":"15","author":"Zhang","year":"2017","journal-title":"Mol. Cancer Res."},{"issue":"11","key":"10.1016\/j.tranon.2026.102921_bib0009","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41422-020-0374-x","article-title":"Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma","volume":"30","author":"Chen","year":"2020","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.tranon.2026.102921_bib0010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41467-021-21043-4","article-title":"Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102921_bib0011","doi-asserted-by":"crossref","DOI":"10.1155\/mi\/9028037","article-title":"Single-cell transcriptomics reveals biomarkers for NK cell dysfunction in endometriosis-associated immune dysregulation","volume":"2026","author":"Li","year":"2026","journal-title":"Mediat. Inflamm."},{"issue":"8","key":"10.1016\/j.tranon.2026.102921_bib0012","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.tranon.2026.102921_bib0013","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.tranon.2026.102921_bib0014","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.tranon.2026.102921_bib0015","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.tranon.2026.102921_bib0016","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.62347\/BQFH7352","article-title":"In vitro co-culture models for studying organoids-macrophages interaction: the golden technology of cancer immunotherapy","volume":"14","author":"Liu","year":"2024","journal-title":"Am. J. Cancer Res."},{"issue":"19","key":"10.1016\/j.tranon.2026.102921_bib0017","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1158\/1078-0432.CCR-07-4761","article-title":"IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression","volume":"14","author":"Hatano","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102921_bib0018","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41564-024-01659-0","article-title":"Interferon-induced transmembrane protein-1 competitively blocks ephrin receptor A2-mediated Epstein-Barr virus entry into epithelial cells","volume":"9","author":"Yang","year":"2024","journal-title":"Nat. Microbiol."},{"issue":"42","key":"10.1016\/j.tranon.2026.102921_bib0019","doi-asserted-by":"crossref","first-page":"35484","DOI":"10.1074\/jbc.M112.367532","article-title":"Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients","volume":"287","author":"Li","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.tranon.2026.102921_bib0020","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2008-02-142596","article-title":"Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells","volume":"113","author":"Klibi","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2026.102921_bib0021","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1186\/s12885-024-13114-8","article-title":"Integrated bulk and single-cell profiling characterize sphingolipid metabolism in pancreatic cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"issue":"19","key":"10.1016\/j.tranon.2026.102921_bib0022","doi-asserted-by":"crossref","first-page":"10549","DOI":"10.18632\/aging.205094","article-title":"Identifying endoplasmic reticulum stress-related molecular subtypes and prognostic model for predicting the immune landscape and therapy response in pancreatic cancer","volume":"15","author":"Zhang","year":"2023","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1016\/j.tranon.2026.102921_bib0023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ijc.2910260202","article-title":"Establishment of a cell line (NPC\/HK1) from a differentiated squamous carcinoma of the nasopharynx","volume":"26","author":"Huang","year":"1980","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2026.102921_bib0024","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41419-024-06671-0","article-title":"Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.tranon.2026.102921_bib0025","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12672-024-01220-9","article-title":"Hsa_circ_ROBO1 competes with miR-324-3p and upregulates NME1 to promote tumor metastasis in nasopharyngeal carcinoma","volume":"15","author":"Liang","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.tranon.2026.102921_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010091","article-title":"FOXA1 enhances antitumor immunity via repressing interferon-induced PD-L1 expression in nasopharyngeal carcinoma","volume":"12","author":"Ge","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2026.102921_bib0027","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"issue":"5168","key":"10.1016\/j.tranon.2026.102921_bib0028","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1126\/science.8016643","article-title":"Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA","volume":"265","author":"Steimle","year":"1994","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.tranon.2026.102921_bib0029","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1158\/2767-9764.CRC-23-0091","article-title":"MHC class II is induced by IFN\u03b3 and follows three distinct patterns of expression in colorectal cancer organoids","volume":"3","author":"Pickles","year":"2023","journal-title":"Cancer Res. Commun."},{"issue":"7","key":"10.1016\/j.tranon.2026.102921_bib0030","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/jso.21728","article-title":"Macrophage migration inhibitory factor contributes angiogenesis by up-regulating IL-8 and correlates with poor prognosis of patients with primary nasopharyngeal carcinoma","volume":"102","author":"Liao","year":"2010","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.tranon.2026.102921_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.791187","article-title":"Exosomal MIF derived from nasopharyngeal carcinoma promotes metastasis by repressing ferroptosis of macrophages","volume":"9","author":"Chen","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.tranon.2026.102921_bib0032","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/1471-2407-6-283","article-title":"Exosomes released from EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9","volume":"6","author":"Keryer-Bibens","year":"2006","journal-title":"BMC Cancer"},{"issue":"21","key":"10.1016\/j.tranon.2026.102921_bib0033","doi-asserted-by":"crossref","first-page":"13326","DOI":"10.1128\/JVI.79.21.13326-13337.2005","article-title":"In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin","volume":"79","author":"Pioche-Durieu","year":"2005","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.tranon.2026.102921_bib0034","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12390","article-title":"Extracellular vesicles derived from nasopharyngeal carcinoma induce the emergence of mature regulatory dendritic cells using a galectin-9 dependent mechanism","volume":"12","author":"Lefebvre","year":"2023","journal-title":"J. Extracell. Vesicles"},{"issue":"3","key":"10.1016\/j.tranon.2026.102921_bib0035","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41423-024-01253-8","article-title":"Cell-associated galectin 9 interacts with cytotoxic T cells confers resistance to tumor killing in nasopharyngeal carcinoma through autophagy activation","volume":"22","author":"Kam","year":"2025","journal-title":"Cell Mol. Immunol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102921_bib0036","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41389-020-00248-0","article-title":"Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation","volume":"9","author":"Zhang","year":"2020","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1016\/j.tranon.2026.102921_bib0037","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102921_bib0038","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13058-016-0683-7","article-title":"Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a STAT2-dependent manner","volume":"18","author":"Ogony","year":"2016","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102921_bib0039","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2017.04.005","article-title":"IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK\/STAT-mediated induction of p21","volume":"399","author":"Lui","year":"2017","journal-title":"Cancer Lett."},{"issue":"36","key":"10.1016\/j.tranon.2026.102921_bib0040","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.tranon.2026.102921_bib0041","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102921_bib0042","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejca.2022.06.034","article-title":"Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1\/PD-L1 inhibitors in real-world head and neck and lung cancer patients","volume":"174","author":"Foy","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"19","key":"10.1016\/j.tranon.2026.102921_bib0043","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.tranon.2026.102921_bib0044","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomized, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.tranon.2026.102921_bib0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:24:44Z","timestamp":1787225084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"alternative-id":["S1936523326002573"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102921","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-cell sequencing reveals an immunotherapy-relevant IFITM1-marked epithelial interferon state in nasopharyngeal carcinoma","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102921"}}